It goes by many names; AS4, Andarine, And-S4, S4 Andarine, and sometimes it’s even called just S4. Regardless of what you refer to the substance as, it is an investigational selective androgen receptor modulator, or SARM. Remember, SARMs are capable of being very selective in their action, depending on use case. That’s what sets them apart form anabolic steroids and other limited use substances.
As is the case with a many different SARMs, Andarine S4 is frequently used and abused by the fitness community. Known for having undeniably strong effects on bone density, muscle gains, and even fat burn, you can understand the allure. These physique changes are only a small portion of what Andarine S4 could be used for. That’s why we are making it a point to offer you high quality S4, suspended in Polyethylene glycol, for laboratory and research use at an affordable price.
Alternate Use Cases
As we said, leveraging Andarine S4 for body building isn’t all that is available to science and modern medicine. Some impressive research has been completed over the past decade. Let’s take a look at a quick timeline of where we started with Andarine S4 research and where we are today.
- June 2005 – Jiyun Chen, Juhyun Kim, and a gentleman by the name of James Dalton discovered that Andarine S4 was therapeutic in cells from individuals struggling with osteoporosis. Remember, osteoporosis is an uncurable condition where reduced mass makes the bones weak. This research was just the start.
- October 2007 – Just two years later, James Dalton was involved in a study that proved out the theory his team derived from the 2005 study: Andarine could be used to prevent bone loss in rats. (…and presumably humans.)
- July 2010 – Building off from Dalton’s work, studies started to appear with a focus on investigating therapies and potential regimens for humans suffering from sever osteoporosis.
- June 2015 – Ten years after the initial studies began. Therapies for musculoskeletal diseases are thought to be treatable and regulated utilizing SARMs like Andarine S4.
So What Does the Future Hold?
Well, that really is going to depend on the amount of research completed over the coming few years. It’s reasonable to expect that FDA will approve further testing on humans for the use of SARMs in osteoporosis treatment, but what about musculoskeletal disorders? The three major ones are carpal tunnel syndrome and tendinitis. There is a good chance that you or somebody you know very well will suffer from one of the two in your lifetime. Perhaps medications to help treat the effects will be derived from Andarine S4 or use Andarine S4 as the main ingredient. Heck, maybe there will be a cure!
The risks and side effects are probably the reason more research hasn’t been completed. It’s difficult trying to battle the negatives. Not unlike anabolic steroids, the most common side effects include high blood pressure, hair loss, a lack of testosterone and increase in estrogen, and acne. These side effects come whether you’re using the SARM for body building or for treatment against diseases and/or disorders. Trying to weed out these side effects is definitely the next step for medical research. If somebody should find success there, they might have a real beauty on their hands.
1 Jiyun Chen, Juhyun Kim, James T. Dalton. “Discovery AND Therapeutic Promise OF Selective Androgen Receptor Modulators.” Mol Interv., U.S. National Library of Medicine, Nov. 2009, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2072877/.
2 Jeffrey D. Kearbey, Wenqing Gao, Ramesh Narayanan, Scott J. Fisher, Di Wu, Duane D. Miller, James T. Dalton. “Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats.” Pharm Res., U.S. National Library of Medicine, Oct. 2007, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039878/.
3 Shalender Bhasin, Ravi Jasuja. “Selective Androgen Receptor Modulators (SARMs) as Function Promoting Therapies.” Curr Opin Clin Nutr Metab Care., U.S. National Library of Medicine, Jul. 2010, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907129/.
4 Christian M. Girgis, Nancy Mokbel, Douglas J. DiGirolamo. “Therapies for Musculoskeletal Disease: Can we Treat Two Birds with One Stone?.” Curr Osteoporos Rep., U.S. National Library of Medicine, Jun. 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083371/.